As of September 16, 2026, lecanemab and donanemab are FDA-approved and shown in trials to clear amyloid plaque and slow cognitive decline. The discussion has since moved from the drugs themselves to access: a 12-month wait on a treatment list leaves 25 percent of MCI and 50 percent of mild dementia patients ineligible, and in the U.S. a PET scan or CSF is still required to qualify. Falsely reassuring a patient that memory loss is normal can delay diagnosis by a year and a half or more. The Alzheimer's Association's $100 million push into a possible GLP-1 link remains open.